680 reports of this reaction
1.3% of all DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS reports
#14 most reported adverse reaction
MOBILITY DECREASED is the #14 most commonly reported adverse reaction for DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS, manufactured by Accord Healthcare, Inc.. There are 680 FDA adverse event reports linking DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS to MOBILITY DECREASED. This represents approximately 1.3% of all 50,803 adverse event reports for this drug.
Patients taking DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS who experience mobility decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MOBILITY DECREASED is a less commonly reported adverse event for DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS, but still significant enough to appear in the safety profile.
In addition to mobility decreased, the following adverse reactions have been reported for DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS:
The following drugs have also been linked to mobility decreased in FDA adverse event reports:
MOBILITY DECREASED has been reported as an adverse event in 680 FDA reports for DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS. This does not prove causation, but indicates an association observed in post-market surveillance data.
MOBILITY DECREASED accounts for approximately 1.3% of all adverse event reports for DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS, making it a notable side effect.
If you experience mobility decreased while taking DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.